Immunohistochemical expression of Cyclooxygenase-2 in colorectal carcinoma and its association with clinicopathological parameters

Payman MS. Salim; Saman S. Abdulla; Jalal A. Jalal

doi:10.15218/zjms.2019.044

Authors

Payman MS. Salim Department of Histopathology, Rizgary Teaching Hospital, Erbil, Iraq.
Saman S. Abdulla Department of Oral Diagnosis and Medicine, College of Dentistry, Hawler Medical University, Erbil, Iraq.
Jalal A. Jalal Department of Pathology, College of Medicine, Hawler Medical University, Erbil, Iraq.

DOI:

https://doi.org/10.15218/zjms.2019.044

Keywords:

Cylooxygenase-2, Colorectal carcinoma, Immunohistochemistry, Histopathology

Abstract

Background and objective: Inflammatory process and genetic factors play a key role in neoplasia of colorectal cancer. Cyclooxygenase-2 is involved in a variety of important cellular functions, including cell growth and differentiation, cancer cell motility and invasion, angiogenesis, and immune functions. This study aimed to evaluate the frequency of cyclooxygenase-2 in colorectal cancer and its correlations with different clinicopathological parameters.

Methods: A study carried out in the Department of Pathology in Rizgary Teaching Hospital and private laboratories in Erbil city from May 2015 to February 2016. Eighty formalin-fixed paraffin-embedded specimens of colorectal cancers were collected. The clinicopathological data was collected by the researcher from records of known cases of colorectal carcinoma in Erbil city and was done in a private laboratory in Dohuk city.

Results: High cyclooxygenase-2 expression was represented by 63.8% of colorectal carcinoma patients, and low expression was represented by 36.2% of them. There was a significant association between the mucinous subtype of colorectal carcinoma and low cyclooxygenase-2 expression (P = 0.01). A significant association was observed between moderately differentiated carcinoma and high cyclooxygenase-2 expression (P = 0.04). A significant association was also noted between increased tumor size and high cyclooxygenase-2 expression (P = 0.03).

Conclusion: Cyclooxygenase-2 expression is more likely to be prevalent among colorectal carcinoma patients and is correlated to tumor subtypes (low in mucinous subtypes), grade (high in moderately differentiated), and tumor size (high in the big sized tumor).

Metrics

Metrics Loading ...

References

Siegel RL, Miller KD, Ahmedin Jemal DVM. Cancer statistics, 2016. CA: A CJC 2016; 66:7–30.

Results of Iraqi Cancer Registry (1999-2004), Ministry of health, Iraq Cancer Registry Centre, Baghdad – Iraq; 2008.

Dempke W, Rie C, Grothey A. Cyclooxygenase-2: A novel target for cancer chemotherapy. J Cancer Res Clin Oncol 2001; 127:4117.

Karahan N, Güney M, Baspinar S. Expression of gelatinase (MMP-2 and MMP-9) and cyclooxygenase-2 (COX-2) in endometrial carcinoma. Eur J Gynaeol Oncol 2007; 28:184–8.

Mahmoud AS, Umair A, Azzeghaiby SN, Hussain F, Hanouneh S, Tarakji B. Expression of cyclooxygenase-2 (COX-2) in colorectal adenocarcinoma: An immunohistochemical and histopathological study. Asian Pac J Cancer Prev 2014; 15:6787–90.

Onoshita M, Takaku K OM. Cyclooxygenase-2 expression in fibroblasts and endothelial cells of intestinal polyps. Cancer Res 2002; 62:6846–9.

Zhou LH, Hu Q SH. Tanshinone II-a inhibits angiogenesis through down regulation of COX-2 in human colorectal cancer. Asian Pac J Cancer Prev 2012; 13:4453–8.

Tuynman JB, Buskens KK. Neo-adjuvant selective cox-2 inhibition down-regulates important oncogenic pathway with esophageal adenocarcinoma. Ann Sur 2005; 242–9.

Hamilton SR, Bosman FT, Boffetta P. Carcinoma of the colon and rectum. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumors of the digestive system. Lyon: IARC Press; 2010. P. 134–46.

Almhanna K, El-Rayes B, Sethi S, Dyson G, HeilbrunL, Philip P A, et al. Association between COX-2 expression and effectiveness of COX-2 inhibitors in phase II trial in patients with metastatic colorectal adenocarcinoma. Anticancer Res 2012; 32(8):3559–63.

Jang SM, Jun YJ, Na W, Jang SH, Min KW, Song YS, et al. Clinicopathologic significance of cyclooxygenase-2 overexpression in colorectal adenocarcinom. BAP 2010; 3(1):14–20.

Kazem A, El Sayed K, El Kerm Y. Prognostic significance of COX-2 and b-catenin in colorectal carcinoma. AJM 2014; 50:211–20.

Hussein AA, Ibrahim BM, Kashman BM. The expression of Matrix metalloproteinase-2 and cyclooxygenase-2 by immunohistochemistry in patients with colorectal carcinoma. J Fac Med Baghdad 2011; 53(3):301–5.

Wu Q-B, Sun G-P. Expression of COX-2 and HER-2 in colorectal cancer and their correlation: WJG 2015; 21(20):6206–14.

Peng L, Zhou Y, Wang Y, Mou H, Zhao Q. Prognostic significance of COX-2 immunohistochemicalexpression in colorectal cancer: A meta-analysis of the literature. PLoS One 2013; 8(3):e58891.

Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S, et al. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 2000; 6(10):4064–8.

Yang Q, Liu Y, Huang Y, Huang D, Li Y, Wu J, et al. Expression of COX-2, CD44v6 and CD147 and relationship with invasion and lymph node metastasis in hypopharyngeal squamous cell carcinoma. PLoS One 2013; 8(9):e71048.

Joo Y-E, Kim H-S, Min S-W, Lee W-S, Park C-H, Park C-S, et al. Expression of Cyclooxygenase-2 protein in colorectal carcinomas. Int J Gastroint Cancer 2002; 31(1–3):147–54.

Sheehan KM, Sheahan K, O’Donoghue DP, MacSweeney F, Conroy RM, Fitzgerald DJ, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 2000; 282:1254–7.

Coget J, Borrini F, Susman S, Sabourin JC. Colorectal carcinomas in 2013: the search for powerful prognostic markers is still on the go. Cancer Biomark 2014; 14(2-3):145–50.

Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 2005; 23:2840–55.

Cianchi F, Cortesini C, Bechi P. Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 2001; 121:1339–47.

Bertagnolli MM, Eagle CJ, Zauber AG. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355:873–84.

Arber N, Eagle CJ, Spicak J. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355:885–95.

Yamac D, Celenkoglu G, Coskun U. Prognostic importance of COX-2 expression in patients with colorectal cancer. Pathol Res Pract 2005; 201:497–502.

Joo YE, Kim HS, Min SW. Expression of cyclooxygenase-2 protein in colorectal carcinomas. Int J Gastrointest Cancer 2002; 31:147–54.

LI H, Guo Q, Zhou B, He S. Cyclooxygenase-2 gene polymorphisms and the risk of colorectal cancer: A population-based study. Oncology Letters 2015; 10(3):1863–9.

Peng Q, Yang S, Lao X, Tang W, Chen Z, Lai H, et al. Meta-analysis of the association between COX-2 polymorphisms and risk of colorectal cancer based on case–control studies. PLoS One 2014; 9(4):e94790.